A5074956526- Schizophrenia research and treatment
- Bipolar Disorder and Treatment
- Mental Health Treatment and Access
- Treatment of Major Depression
- Mental Health and Psychiatry
- Health Systems, Economic Evaluations, Quality of Life
- Pharmaceutical studies and practices
- Systemic Sclerosis and Related Diseases
- Computational Drug Discovery Methods
- Phytochemical and Pharmacological Studies
- Bone health and treatments
- Immunodeficiency and Autoimmune Disorders
- Maternal Mental Health During Pregnancy and Postpartum
- Mental Health and Patient Involvement
- Tryptophan and brain disorders
- Ultrasound and Hyperthermia Applications
- Blood groups and transfusion
- Innovation Policy and R&D
- Luminescence Properties of Advanced Materials
- Drug-Induced Adverse Reactions
- Bone Tumor Diagnosis and Treatments
- Employment and Welfare Studies
- Plant Pathogenic Bacteria Studies
- Gastrointestinal Bleeding Diagnosis and Treatment
- Adrenal and Paraganglionic Tumors
Janssen (Hungary)
2013-2023
Semmelweis University
1987-2015
We conducted a matched-cohort study to assess mortality in schizophrenia and the relationship of with comorbid somatic conditions suicide attempts.A full-population register-based prospective was performed including all eligible patients Hungary between 01/01/2005 31/12/2013. Control subjects were individually matched at 5:1 ratio. The principal outcome measure death due any reason. A non-parametric approach used for descriptive statistical purposes, Kaplan-Meier model survival analysis, Cox...
Purpose Treatment-resistant depression (TRD) is associated with a poor quality of life and high economic burden. This observational retrospective epidemiological study aimed to estimate the proportion patients TRD within cohort major depressive disorder (MDD) in Hungary examine mortality comorbidities without TRD. Patients methods included MDD who experienced onset new episode between 01 January 2009 31 August 2015, using data from nationwide, longitudinal database. Results Overall, 99,531...
Background Schizophrenia is a severe condition that affects approximately 1% of the population. Certain elements antipsychotic treatment can only be examined in large population, thus need for population-based real-world analyses has been increasing. Patients and methods Hungarian National Health Fund database includes all healthcare data population Hungary. All patients diagnosed with schizophrenia between 01.01.2006 31.12.2015 were included study. We analyzed newly initiated...
Greater 1-year and 2-year treatment continuation rates longer median time to discontinuation for second-generation antipsychotic (SGA) long-acting injectables (LAIs) vs oral antipsychotics (OAPs) in Hungary were previously reported. This study reports an updated comparison between new LAIs OAPs Hungary. De-identified claims data from Hungarian National Health Insurance Fund database of schizophrenia patients who newly initiated on SGAs (November 01, 2016 June 30, 2017) retrospectively...